Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AP31969
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Canaan
Deal Size : $47.6 million
Deal Type : Series B Financing
Acesion Pharma Closes Oversubscribed €45M Series B Financing Round to Advance Development of Nov...
Details : The financing will be used to advance the clinical development of AP31969, an SK ion channel inhibitor optimised for chronic oral treatment of atrial fibrillation.
Brand Name : AP31969
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 26, 2023
Lead Product(s) : AP31969
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Canaan
Deal Size : $47.6 million
Deal Type : Series B Financing
Lead Product(s) : AP31969
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Acesion Pharma Announces Positive Pre-Clinical Data for AP31969
Details : AP31969 is the second-generation oral SK ion channel inhibitor, which is being developed for chronic oral maintenance treatment to prevent AF recurrence.
Brand Name : AP31969
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 15, 2023
Lead Product(s) : AP31969
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AP30663
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Positive Phase 2 Data from Atrial Fibrillation Clinical Trial – Primary Endpoint Met
Details : AP30663 is a first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm. It is being developed for the treatment of atrial fibrillation.
Brand Name : AP30663
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 14, 2023
Lead Product(s) : AP30663
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?